Velocity Announces Three Leadership Hires in Europe
01/24/2023Velocity Clinical Research (“Velocity”), the largest integrated research site organisation globally, today announces it has strengthened its European senior executive team with three strategic hires, as the firm continues its expansion in the region.
Clinical Trials: What You Need to Know for 2023
01/23/2023 | PatientsIt is well known that fragmentation of the clinical sites business has been identified as a market opportunity by private equity firms. As a result of a PE capital injection, there has been increased merger and acquisition activity within the sector, leading to a level of consolidation that signals a maturing market.
Velocity U.S. Patient Survey 2022
By Paul Evans | 09/28/2022 | PatientsSurveyTechnology
Velocity U.S. Patient Survey 2022 - Print Version
By Paul Evans | 09/27/2022 | PatientsSurveyTechnology
Velocity Acquires MedPharmics
09/01/2022 | AcquisitionsVelocity adds 8 sites across the gulf coast with the addition of Medpharmics.
Velocity Clinical Research begins European expansion with German site acquisition
07/27/2022 | AcquisitionsVelocity acquires Clinical Research Hamburg. Officially planting the Velocity flag in Europe.
Velocity and Ripple Science Sign Pilot Agreement for Ripple Recruit Software
04/19/2022 | TechnologyVelocity partners with Ripple Science to optimize the patient recruitment process. Ripple's recruitment tools with greatly help make the recruitment process be more effective and efficient.
Preventing Alzheimer's disease is goal of breakthrough therapy
03/01/2022Velocity is working to prevent Alzheimer's disease through clinical research
Velocity TrierHealth, appoints Raghu Punnamraju as CTO
02/22/2022 | TechnologyAcquisitionsVelocity acquires TrierHealth establishing a tech hub in Hyderabad focused on the development of patient focused technology.
Was the COVID-19 vaccine developed too quickly and should you trust it?
By Dr Paul Evans, Chief Executive Officer | 07/23/2021
Finding a COVID-19 vaccine took a gargantuan effort, and remarkably in less than a year, one was found.
Durham clinical ﬁrm continues expansion streak under new owner
By Sonia Waraich, Triangle Business Journal | 06/30/2021 | Acquisitions
Velocity Clinical Research announced Wednesday that it’s acquired two additional sites – Clarity Clinical Research in New York and Providence...
Velocity Clinical Research acquired by GHO signaling evolution of clinical trial site industry
Velocity Clinical Research acquires two new sites, signaling commitment to diversifying patient recruitment
Velocity Executive Memo Series, Vol. 2
By Dr. Paul Evans | 03/01/2021What do teenagers and over 65s have in common?
Velocity Executive Memo Series, Vol. 1
By Dr. Paul Evans | 02/01/2021COVID-19, Our work is not done.
Velocity Acquires Omega Medical Research and Buynak Clinical Research, Expanding Its Reach to All Four Continental U.S. Time Zones
06/08/2020Velocity Acquires Omega Medical Research and Buynak Clinical Research, Expanding Its Reach to All Four Continental U.S. Time Zones
Spotlight on Real World Challenges Facing Virtual Trials - Interview with CEO, Paul Evans
06/08/2020“We’re still living with this black swan moment, this pandemic,” says Evans. While the industry has adapted and embraced new technologies and ideas, there’s a chance the changes won’t stick, Evans says. “Memories can be short, and people can revert back to type, and the [clinical trial industry] isn’t historically quick to adapt. I hope we don’t slide back into our old ways,” he says in our June 4, 2020 interview.
Durham startup Velocity Clinical doubles in size with latest acquisitions
11/06/2019Velocity Clinical Research is doubling in size with its latest acquisitions announced today. The Durham-based clinical site organization has acquired Advanced Clinical Research (ACR) and Rapid Medical Research (RMR), adding six sites to the existing organization.
Velocity Clinical Doubles its Size with New Acquisitions including Advanced Clinical Research and Rapid Medical Research and Evidences Commitment to Vision
11/06/2019The Clinical investigational site market continues to get more interesting by the day. Private equity-backed Velocity Clinical Research, led by industry veteran Paul Evans, acquired more regional clinical sites, adding six of them while in the process, expanding its footprint to 10 sites in seven states. The company is executing to a strategic vision for a high impact, scaled out clinical investigational site operation that over time could rival some contract research organizations.
People on the Move: Outsourcing-Pharma roundup August ‘19 -- Melissa Holbrook
09/05/2019Velocity Clinical Research expanded its senior management team this month with the addition of Melissa Holbrook as VP, Operations
Durham startup Velocity Clinical adds new exec, forecasts doubling in size by year-end
09/04/2019With plans to double in size by the year’s end, Velocity Clinical Research is adding to its executive team to keep up with its exponential growth.
Durham clinical company bolsters C-suite for 'growth spurt'
09/03/2019Following its launch-year acquisitions, Velocity Clinical Research is shuffling its executive team to prepare for an impending "growth spurt."
Sponsors Want to Hear from Sites—With Evidence
09/03/2019Join Melissa Holbrook at the ACRP Southeast Regional Conference in Durham, NC, October 3-4 for a panel discussion on the importance of a great CRO and site relationship.
Velocity Clinical Research Snags Industry Expert Melissa Holbrook for New VP Operations Position
08/29/2019Velocity Clinical Research is delighted to announce that its senior management team is expanding again this year. Melissa Holbrook joins the Velocity Clinical team as VP Operations, and will be responsible for clinical operations at all of Velocity’s sites.
Durham clinical research company expands on West Coast
05/28/2019Just months after launching, a new Durham clinical trial organization has already added a new site to its portfolio – the first of many in the company's growth plan.
Velocity Clinical expands its footprint yet again with 4th acquisition this year
05/28/2019The Durham-based company has acquired its fourth site in almost as many months, adding a new state-of-the-art clinical research facility in Oregon.
Velocity Clinical Research adds new OR-based site
05/28/2019Following its formal launch in February 2019, Velocity Clinical Research adds to its site network to tap into a new patient population, says CEO.
Velocity Clinical Research: The Value-Added Site Organization Designed to Raise the Research Bar
04/20/2019Velocity Clinical Research recently announced important additions to its senior leadership team including: Jeffrey Jensen, Senior Vice President, Operations; Jamie Wilkerson, Vice President, Finance and Craig M. Koch, Vice President, Business Development.
Durham-based Velocity Clinical’s new management team
04/10/2019Velocity Clinical Research is hoping to disrupt the quickly changing business of clinical trails and patient recruitment. Now it’s got its A-team to help it do just that.
Velocity Clinical Research snares $20M-plus in funding, acquires 3 research sites
02/13/2019Velocity Clinical Research, a Durham, North Carolina-based patient recruitment specialist, used $20 million from a recent fundraising to acquire its first three research sites.
Gaining Velocity: New site organization aims to solve age-old problem
02/07/2019Velocity Clinical Research officially launches following the acquisition of three US-based sites – with plans to expand globally and become one of the leading site groups in the world, says CEO.
Velocity Clinical Research Raises the Bar for Patient Recruitment
02/06/2019Velocity Clinical Research, a clinical trials site organization focused on setting a new bar for providing rapid data delivery with the highest level of patient care, has announced it has acquired its first three research sites in the USA.
Durham-based Velocity Clinical raises more than $20M to purchase 3 research sites
02/05/2019The business of clinical trials and patient recruitment is changing quickly, and Velocity Clinical Research is hoping to capitalize on that.